EUVIMEDScopri EUVIMED
Crossref

Botulinum Toxin Type A Timing Efficacy in Patients With Synkinesis After Bell's Palsy

Abdurrahman Al-Awady iD, Vivek Annadata, Ryan Sicard, Avanish Yendluri, Joshua Rosenberg, Mingyang Gray

Otolaryngology–Head and Neck Surgery · 2025

DOI: 10.1002/ohn.1205 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2025. Written by Abdurrahman Al-Awady and 5 co-authors. Institution: Divison of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, Ne…. Major MEDLINE topics: Botulinum Toxins, Type A, Bell Palsy, Synkinesis, Neuromuscular Agents. Cited 1 times so far (Crossref); 47 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Objective

This study examines whether the timing of botulinum toxin type A (BoNTA) treatments affects outcomes in patients with synkinesis, a sequela of Bell's Palsy characterized by disconjugate facial muscle movement. Study Design A retrospective chart review.

Setting

An urban academic medical center.

Methods

We reviewed the charts of synkinesis patients treated from 2016 to 2022. Data included procedural notes, intervention dates, and scores from the House–Brackmann (HB), Facial Clinimetric Evaluation (FaCE), Synkinesis Assessment Questionnaire (SAQ), and Facial Grading System (FGS).

Results

Sixty‐seven patients (median age 54 years, average palsy duration 5.7 years) received BoNTA. Patients treated within 12 months (n = 28), 13 to 24 months (n = 12), and after 24 months (n = 23) showed no significant differences in changes to HB, FaCE, or SAQ scores. However, patients treated within 1 year had significantly higher FGS improvement (36.3) than the other groups ( P = .03).

Conclusion

While FaCE, HB, and SAQ scores showed no significant differences, early BoNTA treatment within 1 year significantly improved FGS scores, indicating better outcomes. Therefore, early treatment is ideal for optimal response.

Subjects

MeSH terms (MEDLINE)

Botulinum Toxins, Type ABell PalsySynkinesisNeuromuscular AgentsHumansRetrospective StudiesMaleFemaleMiddle AgedTreatment OutcomeTime FactorsAdultAged

Author keywords

Bell's palsybotulinum toxinfacial plasticssynkinesis

Substances

Botulinum Toxins, Type ANeuromuscular Agents

Authors and institutions

  • Divison of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID profiles: Abdurrahman Al-Awady

Cite

APA

Al-Awady, A., Annadata, V., Sicard, R., Yendluri, A., Rosenberg, J., & Gray, M. (2025). Botulinum Toxin Type A Timing Efficacy in Patients With Synkinesis After Bell's Palsy. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1205

Vancouver

Al-Awady A, Annadata V, Sicard R, Yendluri A, Rosenberg J, Gray M. Botulinum Toxin Type A Timing Efficacy in Patients With Synkinesis After Bell's Palsy. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1205

BibTeX
@article{AlAwady2025,
  author = {Al-Awady, Abdurrahman and Annadata, Vivek and Sicard, Ryan and Yendluri, Avanish and Rosenberg, Joshua and Gray, Mingyang},
  title = {Botulinum Toxin Type A Timing Efficacy in Patients With Synkinesis After Bell's Palsy},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2025},
  doi = {10.1002/ohn.1205}
}
Start for free →